Briakinumab (original) (raw)
برياكينوماب هو جسم مضاد وحيد النسيلة طورته أبوت ليستخدم في علاج الصداف والتهاب المفاصل الروماتويدي وداء الأمعاء الالتهابي والتصلب اللويحي وداء كرون. يشبه في تأثيره على إنترلوكن 12 و 23.
| Property | Value |
|---|---|
| dbo:abstract | برياكينوماب هو جسم مضاد وحيد النسيلة طورته أبوت ليستخدم في علاج الصداف والتهاب المفاصل الروماتويدي وداء الأمعاء الالتهابي والتصلب اللويحي وداء كرون. يشبه في تأثيره على إنترلوكن 12 و 23. (ar) Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23. (en) Briakinumab (ABT-874) ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung der Schuppenflechte (Psoriasis) vom Pharmaunternehmen Abbott Laboratories entwickelt wurde. Im Januar 2011 wurde der bereits gestellte Zulassungsantrag wieder zurückgezogen. (de) Briakinumab (ABT-874) est un anticorps monoclonal développé par les Laboratoires Abbott pour le traitement de la polyarthrite rhumatoïde, la maladie de Crohn, la rectocolite hémorragique et la sclérose en plaques. En 2011, le développement de ce médicament a été abandonné aux États-Unis et en Europe. (fr) Il Briakinumab (o ABT-874) è un anticorpo monoclonale di tipo interamente umano, che viene studiato con studi di fase III per il trattamento di psoriasi, artrite reumatoide, malattie infiammatorie croniche intestinali e sclerosi multipla.Il farmaco agisce sull'interleuchina-12 e 23. Viene sviluppato dalla Abbott. (it) |
| dbo:casNumber | 339308-60-0 |
| dbo:fdaUniiCode | 978I8M0P8X |
| dbo:wikiPageID | 25230853 (xsd:integer) |
| dbo:wikiPageLength | 6040 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 991684467 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Cambridge_Antibody_Technology dbr:Psoriasis dbr:Rheumatoid_arthritis dbr:Ustekinumab dbr:Interleukin dbr:Interleukin_12 dbr:Interleukin_23 dbc:Abandoned_drugs dbr:Crohn's_disease dbr:Monoclonal_antibody dbr:Multiple_sclerosis dbr:Clinical_trial dbr:Abbott_Laboratories dbc:Immunosuppressants dbr:Etanercept dbr:Double-blind dbc:AbbVie_brands dbr:Placebo dbr:Inflammatory_bowel_disease dbr:Humira dbr:Psoriasis_Area_Severity_Index dbr:Head-to-head_study |
| dbp:atcPrefix | L04 (en) |
| dbp:atcSuffix | AC09 (en) |
| dbp:bioavailability | N/A (en) |
| dbp:c | 6376 (xsd:integer) |
| dbp:casNumber | 339308 (xsd:integer) |
| dbp:chemspiderid | none (en) |
| dbp:h | 9874 (xsd:integer) |
| dbp:legalStatus | investigational (en) |
| dbp:mabType | mab (en) |
| dbp:n | 1722 (xsd:integer) |
| dbp:o | 1992 (xsd:integer) |
| dbp:s | 44 (xsd:integer) |
| dbp:source | u (en) |
| dbp:target | IL-12 and IL-23 (en) |
| dbp:type | mab (en) |
| dbp:unii | 978 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 459982272 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:wikiPageUsesTemplate | dbt:Antineoplastic-drug-stub dbt:As_of dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Interleukin_receptor_modulators dbt:Monoclonals_for_immune_system dbt:Monoclonal-antibody-stub |
| dcterms:subject | dbc:Abandoned_drugs dbc:Immunosuppressants dbc:AbbVie_brands |
| gold:hypernym | dbr:Antibody |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAntibodies dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Act100030358 yago:Activity100407535 yago:Antibody115027189 yago:Care100654885 yago:Chemical114806838 yago:Compound114818238 yago:Event100029378 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:PsychologicalFeature100023100 yago:Relation100031921 yago:Work100575741 yago:YagoPermanentlyLocatedEntity dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Treatment100658082 yago:Unit109465459 yago:WikicatExperimentalMedicalTreatments umbel-rc:DrugProduct |
| rdfs:comment | برياكينوماب هو جسم مضاد وحيد النسيلة طورته أبوت ليستخدم في علاج الصداف والتهاب المفاصل الروماتويدي وداء الأمعاء الالتهابي والتصلب اللويحي وداء كرون. يشبه في تأثيره على إنترلوكن 12 و 23. (ar) Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23. (en) Briakinumab (ABT-874) ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung der Schuppenflechte (Psoriasis) vom Pharmaunternehmen Abbott Laboratories entwickelt wurde. Im Januar 2011 wurde der bereits gestellte Zulassungsantrag wieder zurückgezogen. (de) Briakinumab (ABT-874) est un anticorps monoclonal développé par les Laboratoires Abbott pour le traitement de la polyarthrite rhumatoïde, la maladie de Crohn, la rectocolite hémorragique et la sclérose en plaques. En 2011, le développement de ce médicament a été abandonné aux États-Unis et en Europe. (fr) Il Briakinumab (o ABT-874) è un anticorpo monoclonale di tipo interamente umano, che viene studiato con studi di fase III per il trattamento di psoriasi, artrite reumatoide, malattie infiammatorie croniche intestinali e sclerosi multipla.Il farmaco agisce sull'interleuchina-12 e 23. Viene sviluppato dalla Abbott. (it) |
| rdfs:label | برياكينوماب (ar) Briakinumab (de) Briakinumab (en) Briakinumab (fr) Briakinumab (it) |
| owl:sameAs | freebase:Briakinumab yago-res:Briakinumab wikidata:Briakinumab dbpedia-ar:Briakinumab dbpedia-de:Briakinumab dbpedia-fa:Briakinumab dbpedia-fr:Briakinumab dbpedia-it:Briakinumab https://global.dbpedia.org/id/3NWWe |
| prov:wasDerivedFrom | wikipedia-en:Briakinumab?oldid=991684467&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Briakinumab |
| is dbo:wikiPageRedirects of | dbr:C6376H9874N1722O1992S44 dbr:ATC_code_L04AC09 dbr:ATCvet_code_QL04AC09 |
| is dbo:wikiPageWikiLink of | dbr:Cambridge_Antibody_Technology dbr:Crohn's_disease dbr:C6376H9874N1722O1992S44 dbr:ATC_code_L04AC09 dbr:ATCvet_code_QL04AC09 dbr:ATC_code_L04 dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Br |
| is foaf:primaryTopic of | wikipedia-en:Briakinumab |